Nectar Lifesciences
16.99
+2.83(+19.99%)
Market Cap₹381.02 Cr
PE Ratio-0.88
IndustryHealthcare
Company Performance:
1D+19.99%
1M+13.19%
6M-36.49%
1Y-49.37%
5Y-7.66%
View Company Insightsright
More news about Nectar Lifesciences
31Oct 25
Nectar Lifesciences Promoters Release Pledged Shares Worth ₹156.76 Crore
Nectar Lifesciences Limited announced that two key promoters, Sanjiv Goyal and Sanjiv HUF, have released 99,46,800 pledged shares, representing 44.35% of shareholding, valued at ₹156.76 crore. Sanjiv Goyal released 55,84,560 shares (24.90%) worth ₹88.01 crore, while Sanjiv HUF released 43,62,240 shares (19.45%) worth ₹68.75 crore. The pledge release was executed by SBICAP Trustee Company Limited. This action does not change the promoters' actual shareholding percentages. The company has filed necessary disclosures in compliance with SEBI regulations.
22Oct 25
Nectar Lifesciences Clears INR 1,338.35 Crore Secured Debt, Strengthens Financial Position
Nectar Lifesciences Limited has fully repaid its secured debt of ₹1,338.35 crore to consortium lenders, including accrued interest. This repayment releases both movable and immovable assets, including current assets, from the consortium charge. The satisfaction of charge was registered with the Registrar of Companies, Punjab and Chandigarh on October 22, 2025. SBICAP Trustee Company Limited acted as the Security Trustee for the lenders. The company has informed the National Stock Exchange of India Limited and BSE Limited about this development in compliance with regulatory requirements.
17Oct 25
Nectar Lifesciences Pushes Sale Completion Date to November 2025
Nectar Lifesciences Ltd. has announced a third extension for the completion of its planned sale to Ceph Lifesciences Private Limited, setting a new target date of November 19, 2025. The transaction involves a slump sale of Nectar's business in manufacturing, distribution, marketing, and sale of active pharmaceutical ingredients and formulations. This extension follows previous target dates of July 7, 2025, and September 16, 2025. The company has complied with regulatory requirements and previously obtained shareholder approval for the transaction at an Extraordinary General Meeting on August 4, 2025.
16Sept 25
Nectar Lifesciences Extends Pharmaceutical Business Sale Deadline, Faces DRI Search
Nectar Lifesciences has extended the completion date for the slump sale of its pharmaceutical business to Ceph Lifesciences Private Limited to October 20, 2025. The sale includes the manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations. Separately, the Directorate of Revenue Intelligence (DRI) conducted search operations at various company premises on September 15, 2025, under the Customs Act, 1962. The company is cooperating with authorities, but the specific allegations and financial impact are currently unknown. Operations continue uninterrupted despite these developments.
16Sept 25
DRI Conducts Search Operations at Nectar Lifesciences Under Customs Act
The Directorate of Revenue Intelligence (DRI) conducted search operations at Nectar Lifesciences Limited's premises under the Customs Act, 1962. The search began on September 15, 2025, at 11:00 AM and concluded later that night. Nectar Lifesciences cooperated fully with DRI officials and stated that regular operations were not impacted. The specific violations or financial implications are not yet ascertainable. The company has made necessary disclosures in compliance with SEBI regulations.
11Aug 25
Nectar Lifesciences Secures Ukrainian GMP Certification for Unit VI Amid Planned Slump Sale
Nectar Lifesciences has received GMP certification from Ukraine's SMDC for its Unit VI facility, valid until April 18, 2026. The certification covers pharmaceutical products for sale in Ukraine or export, adhering to PIC/S, EU, and WHO standards. This achievement comes as the company plans a slump sale of the certified facility, which shareholders have already approved. The Unit VI facility is located in Himachal Pradesh, India. Separately, the company's Board will meet on August 14, 2025, to review Q2 2025 financial results.
06Aug 25
Nectar Lifesciences Submits Revised EGM Proceedings, Addressing Key Resolutions
Nectar Lifesciences held an EGM on August 4, 2025, addressing three key resolutions: appointing Dr. Surulichamy Senthilkumar as Director, approving his role as Wholetime Director (R&D), and considering a business transfer to Ceph Lifesciences Private Limited. The meeting, chaired by Dr. Senthilkumar, lasted from 10:00 AM to 10:20 AM. Voting was conducted through e-voting and ballot, with results pending scrutinizer's report.
04Aug 25
Nectar Lifesciences Holds EGM: Key Resolutions on Director Appointment and Business Transfer
Nectar Lifesciences conducted an Extraordinary General Meeting on August 4, 2025, addressing three crucial resolutions: the appointment of Dr. Surulichamy Senthilkumar as Director, his appointment as Wholetime Director (R&D) for three years, and the potential transfer of business to Ceph Lifesciences Private Limited. The company implemented a dual voting system with e-voting and on-site ballot paper voting. Results will be announced after receiving the scrutinizer's report.
08Jul 25
Nectar Lifesciences to Divest Key Businesses for ₹1,290 Crore
Nectar Lifesciences plans to sell its API, Formulations, and Menthol businesses to Ceph Lifesciences for ₹1,290 crore. The deal is expected to complete by September 20, 2025, subject to approvals. Proceeds will be used for debt repayment, new investments, and shareholder rewards. An EGM is scheduled for August 4, 2025, to seek shareholder approval.
08Jul 25
Nectar Lifesciences Reports Q4 Revenue Decline and Significant Loss
Nectar Lifesciences' Q4 financial results show a 2.28% year-on-year revenue decline to ₹4.29 billion. The company reported a significant loss of ₹576 million, compared to a profit of ₹105 million in the same quarter last year, marking a 648.57% negative swing in the bottom line.
30Apr 25
Nectar Lifesciences Secures 2-Year GMP Certification from Brazil's ANVISA for Key APIs
Nectar Lifesciences Limited's Unit II in Punjab has received a two-year Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for two Active Pharmaceutical Ingredients: Ceftazidime pentahydrate and Ceftriaxone disodium hemiheptahydrate. The certification, valid from April 28, 2025, covers chemical synthesis and sterilization processes, validating the company's manufacturing standards and potentially opening new opportunities in the Brazilian market.
10Mar 25
Nectar Lifesciences' API Facility Faces Critical Observations in Joint European Inspection
Nectar Lifesciences' API manufacturing facility in Punjab, India, received seven observations, including four critical ones, during a joint inspection by EDQM and AEMPS. The company is preparing a CAPA report and will undergo a re-inspection for EuGMP approval. CEO Amit Chadah reaffirmed the company's commitment to quality and compliance standards.
Nectar Lifesciences
16.99
+2.83
(+19.99%)
1 Year Returns:-49.37%
Industry Peers
Sun Pharmaceutical
1,831.60
(+1.18%)
Divis Laboratories
6,477.00
(-0.21%)
Torrent Pharmaceuticals
3,720.60
(-0.26%)
Cipla
1,531.30
(+0.40%)
Dr Reddys Laboratories
1,258.80
(+0.76%)
Lupin
2,082.20
(+0.52%)
Zydus Life Science
942.50
(+0.56%)
Mankind Pharma
2,251.00
(+0.08%)
Aurobindo Pharma
1,226.70
(-0.74%)
Alkem Laboratories
5,685.00
(-0.03%)